Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012
Carbon Monoxide Poisoning
NEJM 360:1217-1225, Weaver,L.K., 2009
Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005
Clinicopath Conf., Colchicine Myoneuropathy
NEJM 349:1656-1663, Case 33-2003, 2003
Early Neurologic Complications Following Allogeneic Bone Marrow Transplant for Leukemia, a Prospective Study
Neurol 50:1441-1445, Antonini,G.,et al, 1998
Mild Traumatic Brain Injury,Toward Understanding Manifestations and Treatment
Arch Int Med 158:90-97, Kushner,D., 1998
Acute Corticosteroid Myopathy in Intensive Care Patients
Muscle & Nerve 20:1371-1380997., Hanson,P.,et al, 1997
Acute Myopathy of Intensive Care:Clinical, Electromyographic, and Pathological Aspects
Ann Neurol 40:645-654, Lacomis,D.,et al, 1996
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Myopathy in Severe Asthma
Am Rev Respir Dis 146:517-519, Douglass,J.A.,et al, 1992
Prognosis in AZT Myopathy
Neurol 41:1181-1184, Chalmers,A.C.,et al, 1991
Zidovudine Myopathy:A Distinctive Disorder Associated with Mitochondrial Dysfunction
Ann Neurol 29:606-614, Mhiri,C.,et al, 1991
Inflammatory Myopathies
NEJM 394:1925-1938, AllenBach,Y. & Benveniste,O., 2026
Clinicopathologic Features, Pathogenesis, and Treatment of Monoclonal Gammopathy-Associated Myopathies
Neurol 105:213101, Soontrapa,P.,et al, 2025
Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025
Niemann-Pick Disease Type C
Gene Reviews www.genereview.org, Bremova-Ertl,T. & Patterson, M., 2025
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
CHANTER Syndrome
Neurol 101:e2338-e2339, Rizkallah,B. & Rubin,D.B., 2023
Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
Ann Neurol 92:201-212, Lindgren, U.,et al, 2022
Spinal Muscular Atrophy
UpToDate, Oct, Bodamer,O.A., 2022
Molecular and Neurological Features of MELAS Syndrome in Paediatric Patients: A Case Series and Review of the Literature
Mal Genet Genomic Med 10:e1955, Seed,L.M.,et al, 2022
Cocaine and Levamisole Cerebral Toxicity
Ann Neurol 89:1253-1254, Allard, J.,et al, 2021
Nitromethane-Induced Acute Reversible Encephalopathy
Neurol 97:e1361-e1362, Palumbo, G.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Subacute Progressive Sensorimotor Symptoms
BMJ 365:doi:10.1136/bmj.l1923, Francis, A.,et al, 2019
Cytotoxic Lesions of the Corpus Callosum Caused by Thermogenic Dietary Supplements
AJNR 40:1304-1308, Galnares-Olalde, J.A.,et al, 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
A Woman in her 40s with Headache and New-Onset Seizures
JAMA Neurol 74:476-480, Graham, M.S.,et al, 2017
Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Clinical Pathologic Conference, West Nile Virus Encephalitis
NEJM 377:1878-1886, Case 34-2017, 2017
Long-Term Benefit of Enzyme Replacement Therapy in Pompe Disease
Neurol 89:2365-2373, Kuperus, E.,et al, 2017
Antibiotic-Associated Encephalopathy
Neurol 86:963-971, Bhattacharyya, S.,et al, 2016
Neonatal Abstinence Syndrome
NEJM 375:2468-2479, McQueen, K. & Murphy-Oikonen, J., 2016
Clinicopathologic Conference, Oligdendroglioma II/IV with IDH1 R132H mutation and codelation of 1p and 19q
NEJM 375:2381-2389, Case 38-206, 2016
Cyclical Konzo Epidemics and Climate Variability
Ann Neurol 77:371-380, Oluwole, O.S.A., 2015
Neurological Manifestations of Scrub Typhus
JNNP 86:761-766, Misra, U.K.,et al, 2015
Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 314:2535-2543,2511, Stupp, R.,et al, 2015
Molybdenum Cofactor Deficiency
Neurol 85:e175-e178, Nagappa, M.,et al, 2015
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia at Diagnosis: Results from the International ALL trial MRC UKALL XII/ECOG E2993
Blood 108:465-472, Lazarus, H.M.,et al, 2015
CBRNE - Nerve Agents, V-series - Ve, Vg, Vm, Vx
emedicine Feb, Keyes, D.C. & Caneva, D.C., 2015
Treatment of Brain Metastases
J Clin Oncol 33:3475-3484, Lin, X. & DeAngelis, L.M., 2015